Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 612

1.

Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.

Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers CL, Weber WA, Scher HI, Morris MJ, Larson SM.

JAMA Oncol. 2018 Feb 1;4(2):217-224. doi: 10.1001/jamaoncol.2017.3588.

PMID:
29121144
2.

In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME).

Pankov D, Sjöström L, Kalidindi T, Lee SG, Sjöström K, Gardner R, McDevitt MR, O'Reilly R, Thorek DLJ, Larson SM, Veach D, Ulmert D.

Oncotarget. 2017 Jul 26;8(39):65917-65931. doi: 10.18632/oncotarget.19579. eCollection 2017 Sep 12.

3.

A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma.

Kramer K, Pandit-Taskar N, Humm JL, Zanzonico PB, Haque S, Dunkel IJ, Wolden SL, Donzelli M, Goldman DA, Lewis JS, Lyashchenko SK, Khakoo Y, Carrasquillo JA, Souweidane MM, Greenfield JP, Lyden D, De Braganca KD, Gilheeney SW, Larson SM, Cheung NV.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26754. Epub 2017 Sep 22.

PMID:
28940863
4.

Theranostic Concepts: More Than Just a Fashion Trend-Introduction and Overview.

Herrmann K, Larson SM, Weber WA.

J Nucl Med. 2017 Sep;58(Suppl 2):1S-2S. doi: 10.2967/jnumed.117.199570. No abstract available.

PMID:
28864608
5.

Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.

Cheal SM, Fung EK, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Wittrup KD, Cheung NV, Larson SM.

J Nucl Med. 2017 Nov;58(11):1735-1742. doi: 10.2967/jnumed.117.193250. Epub 2017 Jul 13.

PMID:
28705917
6.

Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.

Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, Burnazi E, Zhang H, Lewis JS, Blasberg R, Larson SM, Weber WA, Modak S.

J Nucl Med. 2018 Jan;59(1):147-153. doi: 10.2967/jnumed.117.193169. Epub 2017 Jul 13.

PMID:
28705916
7.

Erratum to: Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer.

Osborne JR, Kalidindi TM, Punzalan BJ, Gangangari K, Spratt DE, Weber WA, Larson SM, Pillarsetty NVK.

Mol Imaging Biol. 2017 Dec;19(6):952. doi: 10.1007/s11307-017-1104-8. No abstract available.

PMID:
28695370
8.

Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone.

Harmon SA, Perk T, Lin C, Eickhoff J, Choyke PL, Dahut WL, Apolo AB, Humm JL, Larson SM, Morris MJ, Liu G, Jeraj R.

J Clin Oncol. 2017 Aug 20;35(24):2829-2837. doi: 10.1200/JCO.2017.72.2348. Epub 2017 Jun 27.

PMID:
28654366
9.

Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer.

O'Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schöder H, Larson SM, Beylergil V, Ruan S, Lyashchenko SK, Zanzonico PB, Weber WA, Carrasquillo JA, Janjigian YY.

J Nucl Med. 2018 Jan;59(1):161-166. doi: 10.2967/jnumed.117.194555. Epub 2017 Jun 21.

PMID:
28637800
10.

Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer.

Osborne JR, Kalidindi TM, Punzalan BJ, Gangangari K, Spratt DE, Weber WA, Larson SM, Pillarsetty NVK.

Mol Imaging Biol. 2017 Dec;19(6):944-951. doi: 10.1007/s11307-017-1091-9. Erratum in: Mol Imaging Biol. 2017 Jul 10;:.

11.

Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures.

Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, Chan S, Zhao S, Delgado A, Go J, Beck L, Hurtz C, Ng C, Qiao R, Ten Hoeve J, Palaskas N, Wu H, Müschen M, Multani AS, Port E, Larson SM, Schultz N, Braas D, Christofk HR, Mellinghoff IK, Graeber TG.

Mol Syst Biol. 2017 Feb 15;13(2):914. doi: 10.15252/msb.20167159.

12.

Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).

Abou-Alfa GK, Yen CJ, Hsu CH, O'Donoghue J, Beylergil V, Ruan S, Pandit-Taskar N, Gansukh B, Lyashchenko SK, Ma J, Wan P, Shao YY, Lin ZZ, Frenette C, O'Neil B, Schwartz L, Smith-Jones PM, Ohtomo T, Tanaka T, Morikawa H, Maki Y, Ohishi N, Chen YC, Agajanov T, Boisserie F, Di Laurenzio L, Lee R, Larson SM, Cheng AL, Carrasquilo JA.

Cancer Chemother Pharmacol. 2017 Feb;79(2):421-429. doi: 10.1007/s00280-017-3241-9. Epub 2017 Jan 24.

13.

Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer.

Larson SM, Osborne JR, Grewal RK, Tuttle RM.

Mol Imaging Radionucl Ther. 2017 Feb 9;26(Suppl 1):80-86. doi: 10.4274/2017.26.suppl.09.

14.

Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy.

Larson SM, Truscott LC, Chiou TT, Patel A, Kao R, Tu A, Tyagi T, Lu X, Elashoff D, De Oliveira SN.

Hum Vaccin Immunother. 2017 May 4;13(5):1094-1104. doi: 10.1080/21645515.2016.1268745. Epub 2017 Jan 6.

15.

Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.

Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjöström K, Doran MG, Lamminmäki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, Abou DS, van Voss MR, Scardino PT, Strand SE, Alpaugh ML, Scher HI, Lilja H, Larson SM, Ulmert D.

Sci Transl Med. 2016 Nov 30;8(367):367ra167.

16.

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

Nagarajah J, Le M, Knauf JA, Ferrandino G, Montero-Conde C, Pillarsetty N, Bolaender A, Irwin C, Krishnamoorthy GP, Saqcena M, Larson SM, Ho AL, Seshan V, Ishii N, Carrasco N, Rosen N, Weber WA, Fagin JA.

J Clin Invest. 2016 Nov 1;126(11):4119-4124. doi: 10.1172/JCI89067. Epub 2016 Sep 26.

17.

The epichaperome is an integrated chaperome network that facilitates tumour survival.

Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G.

Nature. 2016 Oct 20;538(7625):397-401. doi: 10.1038/nature19807. Epub 2016 Oct 5.

18.

Corrigendum to "Molecular imaging for personalized cancer care" [Mol. Oncol. 6(2) (2012) 182-195].

Kircher MF, Hricak H, Larson SM.

Mol Oncol. 2016 Dec;10(10):1627. doi: 10.1016/j.molonc.2016.09.006. Epub 2016 Oct 2. No abstract available.

19.

Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.

Pandit-Taskar N, Veach DR, Fox JJ, Scher HI, Morris MJ, Larson SM.

J Nucl Med. 2016 Oct;57(Suppl 3):73S-78S.

20.

Copper-64 labeled liposomes for imaging bone marrow.

Lee SG, Gangangari K, Kalidindi TM, Punzalan B, Larson SM, Pillarsetty NVK.

Nucl Med Biol. 2016 Dec;43(12):781-787. doi: 10.1016/j.nucmedbio.2016.08.011. Epub 2016 Aug 27.

21.

First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.

Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE, Wu AM, Weber WA, Scher HI, Larson SM, Morris MJ.

J Nucl Med. 2016 Dec;57(12):1858-1864. Epub 2016 Aug 11.

22.

A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition.

Anand A, Morris MJ, Kaboteh R, Reza M, Trägårdh E, Matsunaga N, Edenbrandt L, Bjartell A, Larson SM, Minarik D.

J Nucl Med. 2016 Dec;57(12):1865-1871. Epub 2016 Jul 21.

23.

Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism.

Sood A, Miller AM, Brogi E, Sui Y, Armenia J, McDonough E, Santamaria-Pang A, Carlin S, Stamper A, Campos C, Pang Z, Li Q, Port E, Graeber TG, Schultz N, Ginty F, Larson SM, Mellinghoff IK.

JCI Insight. 2016 May 5;1(6). pii: e87030.

24.

Copper-64 trastuzumab PET imaging: a reproducibility study.

Carrasquillo JA, Morris PG, Humm JL, Smith-Jones PM, Beylergil V, Akhurst T, O'Donoghue JA, Ruan S, Modi S, Hudis CA, Larson SM.

Q J Nucl Med Mol Imaging. 2016 May 12. [Epub ahead of print]

PMID:
27171605
25.

Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.

Anand A, Morris MJ, Larson SM, Minarik D, Josefsson A, Helgstrand JT, Oturai PS, Edenbrandt L, Røder MA, Bjartell A.

EJNMMI Res. 2016 Dec;6(1):23. doi: 10.1186/s13550-016-0173-z. Epub 2016 Mar 9.

26.

Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.

Taldone T, Zatorska D, Ochiana SO, Smith-Jones P, Koziorowski J, Dunphy MP, Zanzonico P, Bolaender A, Lewis JS, Larson SM, Chiosis G, Pillarsetty NV.

J Labelled Comp Radiopharm. 2016 Mar;59(3):129-32. doi: 10.1002/jlcr.3369. Epub 2016 Jan 25.

27.

Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling.

Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR, Bander NH, Larson SM, Zanzonico PB, Osborne JR.

EJNMMI Res. 2016 Dec;6(1):7. doi: 10.1186/s13550-016-0164-0. Epub 2016 Jan 22.

28.

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.

Modak S, Zanzonico P, Carrasquillo JA, Kushner BH, Kramer K, Cheung NK, Larson SM, Pandit-Taskar N.

J Nucl Med. 2016 Feb;57(2):231-7. doi: 10.2967/jnumed.115.161752. Epub 2016 Jan 7.

29.

Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.

Schöder H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, Matasar M, Moskowitz A, Noy A, Palomba L, Portlock C, Straus D, Grewal R, Migliacci JC, Larson SM, Moskowitz CH.

J Nucl Med. 2016 May;57(5):728-34. doi: 10.2967/jnumed.115.166769. Epub 2015 Dec 30.

30.

Family Conferences in the Neonatal ICU: Observation of Communication Dynamics and Contributions.

Boss RD, Donohue PK, Larson SM, Arnold RM, Roter DL.

Pediatr Crit Care Med. 2016 Mar;17(3):223-30. doi: 10.1097/PCC.0000000000000617.

31.

Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.

Cheal SM, Xu H, Guo HF, Lee SG, Punzalan B, Chalasani S, Fung EK, Jungbluth A, Zanzonico PB, Carrasquillo JA, O'Donoghue J, Smith-Jones PM, Wittrup KD, Cheung NK, Larson SM.

Eur J Nucl Med Mol Imaging. 2016 May;43(5):925-37. doi: 10.1007/s00259-015-3254-8. Epub 2015 Nov 24.

32.

Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3.

Ahmed M, Cheng M, Zhao Q, Goldgur Y, Cheal SM, Guo HF, Larson SM, Cheung NK.

J Biol Chem. 2015 Dec 11;290(50):30018-29. doi: 10.1074/jbc.M115.679852. Epub 2015 Oct 20.

33.

EXINI Quantitative Bone Scan Index: Expanded Utility for the Planar Radionuclide Bone Scan.

Larson SM.

J Nucl Med. 2016 Jan;57(1):5-6. doi: 10.2967/jnumed.115.164137. Epub 2015 Oct 8. No abstract available.

34.

PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.

Zanzonico P, Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Smith-Jones P, Ruan S, Divgi C, Scott AM, Kemeny NE, Fong Y, Wong D, Scheinberg D, Ritter G, Jungbluth A, Old LJ, Larson SM.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1700-1706. doi: 10.1007/s00259-015-3061-2. Epub 2015 Jul 21.

35.

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Rathkopf DE, Larson SM, Anand A, Morris MJ, Slovin SF, Shaffer DR, Heller G, Carver B, Rosen N, Scher HI.

Cancer. 2015 Nov 1;121(21):3853-61. doi: 10.1002/cncr.29578. Epub 2015 Jul 15.

36.

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.

Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gönen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne JR, Lewis JS, Reuter VE, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ.

Clin Cancer Res. 2015 Dec 1;21(23):5277-85. doi: 10.1158/1078-0432.CCR-15-0552. Epub 2015 Jul 14.

37.

Radioimmunotherapy of human tumours.

Larson SM, Carrasquillo JA, Cheung NK, Press OW.

Nat Rev Cancer. 2015 Jun;15(6):347-60. doi: 10.1038/nrc3925. Review. Erratum in: Nat Rev Cancer. 2015 Aug;15(8):509.

38.

Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.

Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, Smith-Jones P, Bander NH, Scher HI, Larson SM, Morris MJ.

EJNMMI Res. 2015 Apr 29;5:28. doi: 10.1186/s13550-015-0104-4. eCollection 2015.

39.

Age and sex-specific mortality of wild and captive populations of a monogamous pair-bonded primate (Aotus azarae).

Larson SM, Colchero F, Jones OR, Williams L, Fernandez-Duque E.

Am J Primatol. 2016 Mar;78(3):315-25. doi: 10.1002/ajp.22408. Epub 2015 Apr 10.

40.

Response.

Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H.

Radiology. 2015 Feb;274(2):625. No abstract available.

PMID:
25785291
41.

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.

Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ.

J Clin Oncol. 2015 Apr 20;33(12):1356-63. doi: 10.1200/JCO.2014.55.3875. Epub 2015 Jan 26.

42.

Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.

Vilhelmsson-Timmermand O, Santos E, Thorek DL, Evans-Axelsson S, Bjartell A, Lilja H, Larson SM, Strand SE, Tran TA, Ulmert D.

Nucl Med Biol. 2015 Apr;42(4):375-80. doi: 10.1016/j.nucmedbio.2014.12.012. Epub 2014 Dec 23.

43.

Prostate cancer: Better use of bone scans in prostate cancer.

Larson SM.

Nat Rev Urol. 2015 Apr;12(4):190-1. doi: 10.1038/nrurol.2014.305. Epub 2014 Nov 11. No abstract available.

PMID:
25385459
44.

Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe.

Phillips E, Penate-Medina O, Zanzonico PB, Carvajal RD, Mohan P, Ye Y, Humm J, Gönen M, Kalaigian H, Schöder H, Strauss HW, Larson SM, Wiesner U, Bradbury MS.

Sci Transl Med. 2014 Oct 29;6(260):260ra149. doi: 10.1126/scitranslmed.3009524. Epub 2014 Oct 29.

45.

Honoring patients' organ donation decisions when family conflict is present: Experience from a single organ procurement organization.

Stahler PA, Weese SE, Nygaard RM, Hill MJ, Richardson CJ, Larson SM, Gunderson S, Quickel RR.

J Trauma Acute Care Surg. 2014 Oct;77(4):555-8. doi: 10.1097/TA.0000000000000417.

PMID:
25250593
46.

⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.

Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2093-105. doi: 10.1007/s00259-014-2830-7. Epub 2014 Aug 21.

47.

Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex.

Cheal SM, Xu H, Guo HF, Zanzonico PB, Larson SM, Cheung NK.

Mol Cancer Ther. 2014 Jul;13(7):1803-12. doi: 10.1158/1535-7163.MCT-13-0933. Epub 2014 Jun 18.

48.

PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients.

Burger IA, Vargas HA, Apte A, Beattie BJ, Humm JL, Gonen M, Larson SM, Ross Schmidtlein C.

Nucl Med Biol. 2014 May-Jun;41(5):410-8. doi: 10.1016/j.nucmedbio.2014.02.006. Epub 2014 Feb 28.

49.

Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.

Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, Zanzonico P, Larson SM.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):985-94. doi: 10.1007/s00259-013-2679-1. Epub 2014 Mar 7.

50.

Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.

Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H.

Radiology. 2014 Apr;271(1):220-9. doi: 10.1148/radiol.13130625. Epub 2013 Nov 18.

Supplemental Content

Loading ...
Support Center